Policy support for new drug research and development has led to the outbreak of innovative drug industry and the growth of clinical research demand
Driven by the growth of people’s health demand, economic development, policy support, international competition and other internal and external factors, China’s innovative drug industry has developed rapidly. Measured by the number of pipeline products developed, China’s contribution to the world has reached 13.9%, which was only 4.1% in 2015 and 7.8% in 2018. The number of innovative drugs listed in China has also increased steadily in recent years, especially in the field of antitumor drugs.
The R & D investment of China’s pharmaceutical machinery continues to increase, the output results of innovative drugs continue to improve, and the performance of China’s innovative drug enterprises is excellent
The total R & D investment of China’s pharmaceutical machinery has increased from RMB 83.9 billion in 2015 to RMB 183.2 billion in 2019. It is expected to reach RMB 414.2 billion in 2024, and the annual compound growth rate from 2019 to 2024 is expected to be 17.7%. The rise of biotech enterprises, access to a large number of venture capital and IPO Financing for early clinical trials, and a surge in R & D investment; The substantial increase in R & D investment of traditional pharmaceutical companies and obvious head effect are the two core driving forces for the continuous rise in R & D in the field of new drug R & D and medicine.
In 2020, there were 1154 new drug acceptance numbers for CDE, and 559 new drug acceptance numbers for enterprises in the 2021 ranking list of comprehensive strength of drug research and development in China, accounting for 48.44%. Among the 884 class 1 new drugs, there were 1154 acceptance numbers for CDE new drugs in 2020, and 559 new drug acceptance numbers for enterprises in the 2021 ranking list of top 100 in China’s comprehensive drug R & D strength, accounting for 48.44%. Among the 884 class 1 new drugs, about 416 of the top 100 enterprises accounted for 46.83%; Among them, Jiangsu Hengrui Medicine Co.Ltd(600276) is the best. In 2020, 120 new drugs were accepted, including 97 class 1 new drugs (19 biological drugs and 78 chemical drugs)
In the past five years, most clinical trials have been initiated by companies headquartered in China. Among the top ten sponsors, eight are Chinese pharmaceutical enterprises, of which Jiangsu Hengrui Medicine Co.Ltd(600276) ranks first with obvious advantages, and the second is China biopharmaceutical (including its subsidiaries, such as Zhengda Tianqing). There are only two MNCs, Roche and Novartis. Most of the sponsors mainly bid for tumor trials.
